Innate Pharma SA ADR IPHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Outcome of Innate Pharma’s 2026 Annual General Meeting
-
Innate Pharma to participate in the Jefferies Global Healthcare Conference
-
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
-
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
-
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
-
Innate Pharma to Participate in the D. Boral Capital Global Conference
-
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
-
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
Trading Information
- Previous Close Price
- $1.71
- Day Range
- $1.73–1.86
- 52-Week Range
- $1.17–2.63
- Bid/Ask
- $1.76 / $1.78
- Shares Outstanding
- 93.90M
- Market Cap
- $165.27M
- Volume/Avg
- 12,473 / 66,578
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 48.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 163
- Website
- https://www.innate-pharma.com
Valuation
|
Metric
|
IPHA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 48.74 |
Price/Cash Flow | — |
Price/Earnings
IPHA
Financial Strength
|
Metric
|
IPHA
|
|---|---|
Quick Ratio | 1.14 |
Current Ratio | 1.27 |
Interest Coverage | −113.76 |
Quick Ratio
IPHA
Profitability
|
Metric
|
IPHA
|
|---|---|
Return on Assets (Normalized) | −51.64% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −192.58% |
Return on Assets
IPHA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Trkzmfq | Hbjwxq | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Skwbydfhn | Yhncjf | $67B | |||
| argenx SE ADR
ARGX
| Lzvmgdqcy | Hvrf | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Snltwcgg | Sccqlqt | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Xfdnczqfxj | Fphqp | $25B | |||
| BioNTech SE ADR
BNTX
| Mcgjywr | Nzyf | $22B | |||
| Incyte Corp
INCY
| Lvjqxbtj | Vrc | $20B | |||
| Moderna Inc
MRNA
| Hhdffsj | Pdlzz | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Vbkflqrky | Lsfhf | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Pftmmwnb | Spdb | $13B |
United States